TOLL-LIKE RECEPTOR THERAPIES COMPETE TO REDUCE SIDE EFFECTS
An emerging class of highly specific immunomodulator drugs targeting toll-like receptors (TLR) will be the focus of attention this month in Salvador, Brazil. The Conference "Toll2006 - Recent Advances in Pattern Recognition," to be held March 4-7, will explore the latest scientific progress in the field. Among the most advanced players, two companies, Coley Pharmaceuticals of Wellesley, Massachusetts, and Dynavax Technologies of Berkeley, California, are currently in phase 3 clinical trials to bring their TLR-based products on the market. Biotechs joining the fray must now optimize drug efficacy while keeping unwanted immune side effects at bay.